Idiopathic Pulmonary Fibrosis Archives

Galapagos and Gilead to end late-stage studies of lung disease drug

Business, Clinical Trials, Gilead, Idiopathic Pulmonary Fibrosis, Investments, Lung Disease, Partnerships, R&D

Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc. will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis.

February 10, 2021/by Andrew Humphreys

New Pharma Invention Index Picks AstraZeneca as Top Company

Artificial Intelligence, Business, Cancer, Cardiovascular (CV) Death, Chronic Kidney Disease, Coronary Heart Diseases, Heart Attacks, Idiopathic Pulmonary Fibrosis, Invention, Machine Learning, Oncology, Product Pipelines, Strokes, Type 2 Diabetes

AstraZeneca topped the first annual Pharmaceutical Invention Index, released by IDEA Pharma.

November 5, 2019/by BioSpace

Bayer Funds New Joint Research Lab with $30 Million Over 5 Years

Brigham and Women's Hospital, Chronic Lung Disease, COPD, Idiopathic Pulmonary Fibrosis, Laboratory Launches, Massachusetts General Hospital

Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital launched a joint laboratory to research new drugs to treat chronic lung diseases.

September 24, 2019/by BioSpace

Boehringer Ingelheim Lands Positive Results in Lung Disease Trial

Clinical Trials, Connective Tissue, Data, European Medicines Agency, FDA, Idiopathic Pulmonary Fibrosis, merican Thoracic Society (ATS) International Conference, Priority Review Status, R&D, Researchers, Scleroderma, Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), The New England Journal of Medicine (NEJM)

Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.

May 21, 2019/by BioSpace